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Introduction 
The large number of experimental approaches, culture conditions, qualitative and 
quantitative methods, and in vitro and in vivo models employed so far to assess immune 
regulatory properties of multipotent mesenchymal stromal cells (MSCs) has led to an excess 
of literature data that sometimes are poorly comparable, redundant, and even contradictory. 
Thus, quite paradoxically, the risk is that pre-clinical literature data may become eventually 
weak and scarcely useful, in both researchers’ and Regulatory Authorities’ opinion, for 
supporting experimentally specific MSC-based clinical trials aimed at treating autoimmune 
and inflammatory diseases. However, some data in this field appear more solid and 
reproducible and may be generally accepted to suggest reproducible immunological assays 
to quantify the differences in immune modulatory properties of MSCs produced according to 
Good Manufacturing Practice (GMP).  
The MSC Committee of the International Society of Cell Therapy (ISCT) released a 
statement paper in 2005 that established the minimal criteria characterizing human MSCs 
(1), without focusing particularly on their immunological properties. In the 7 years following 
the publication of this statement paper, more than 10,000 manuscripts containing the term 
“mesenchymal stem cell” or “multi-potent mesenchymal stromal cell” in the title or abstract 
have been catalogued in PubMed, and many of them deal with immune regulation. To 
consolidate the scientific research in this field, the MSC Committee of the ISCT is publishing 
a working proposal paper aimed at stimulating the general discussion about the need of 
shared guidelines for the immunological characterization of MSCs for clinical use (Box 1).   
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1. MSCs as immune modulators and the assessment of regulatory properties  
MSCs can be obtained from tissues that originate from distinct development programs and 
that contain distinct pools of endogenous progenitor cells. Therefore, the properties of tissue-
specific MSCs should be carefully evaluated prior to their clinical employment. MSCs or 
MSC-like cells have been identified in bone marrow (2,3), adipose tissue (4), and many other 
tissues and organs (5) including lymphoid tissues (6,7). MSCs have been identified in vivo as 
peri-vascular cells expressing the STRO1, CD146 and 3G5 antigens (8-11). Despite a close 
relationship between these two cell types in terms of surface phenotype and qualitative in 
vitro assays (11,12), MSCs in general lack the contractility of pericytes and may show 
marked differences in gene expression (12), as well as by using more rigorous in vivo assays 
(13). In addition, some Authors have described a neuro-ectodermal origin of MSCs through 
either Sox1+ neuro-epithelial cells (14) or Nestin+ precursors (15). CFU-F–forming cells from 
bone marrow can be obtained through the prospective isolation of CD45-negative MSCs with 
anti-STRO1 (8), -CD271 (16), or -CD146 (17) antibodies, or selection for nestin-expressing 
cells (15). Nevertheless, not enough data concerning purified MSCs are available to assume 
that MSC progenitors/pericytes possess the same immune regulatory properties of ex vivo 
expanded adherent MSCs. Therefore, almost the entire amount of data concerning the 
immunological properties of MSCs refers to as adherent expanded MSCs.    
It is now clear that MSCs of different tissue sources (6,7,18), as well as their stromal progeny 
(19), can interact with, influence and even profoundly affect the in vitro functions of most 
effector cells involved in innate or adaptive immunity (20). These properties have been the 
subject of many excellent reviews (21,22). However, some differences have been described 
amongst MSCs of different tissue origin (7,18); therefore, it cannot be presumed that all 
tissue-derived MSCs display equivalent immunoregulatory properties. We have a better 
appreciation that the in vitro and in vivo molecular mechanisms evoked can be influenced by 
several conceptual and experimental factors, including species and tissue sources of MSCs, 
culture conditions, number of passages determining culture-related senescence, activation 
status of both MSCs and responsive immune effector cells, analytical methods and animal 
models used (21-25). The obvious consequence of this heterogeneity in the scientific 
approach to MSC physiology is that very often in vitro and in vivo data are variable, if not 
contradictory and reciprocally not comparable. This conundrum is far from negligible: the 
assessment of the immune regulatory properties of MSCs is not merely a matter of biological 
speculation but has become the basis for the clinical use of these cells as cellular 
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immunotherapy in different conditions characterized by dysregulated allogeneic or 
autologous immune responses or simply abnormal defensive inflammation (26-32). National 
and international regulatory agencies typically require formal demonstration of the safety and 
effectiveness of the MSC-based treatment strategies in pre-clinical models. There is also an 
expectation that robust potency assays be developed and implemented as part of cell 
manufacturing, which may subsequently be associated with clinical effect and serve as a 
“gold standard” for inter-study analysis.   
After clarifying the nomenclature for MSCs to avoid misunderstanding in comparing stromal 
cells (33), the field has sufficiently matured for a general discussion to reach shared 
guidelines for in vitro and in vivo methodologies defining the functional immune plasticity of 
MSCs. We have broad consensus that flow-cytometry phenotype analysis of MSC cellular 
products represents a minimum definition of identity. In the specific setting of MSCs used for 
immune modulation, the field has defined functionally relevant markers that merit attention 
and highlighted the importance of in vitro MSC licensing to further deploy a functional 
immune phenotype. 
 
1.1. Resting versus primed MSCs: the role of MSC activation 
In a resting state, MSC are at a default niche, displaying mostly bystander anti-apoptotic and 
immune homeostatic features biased toward suppression. These properties can be greatly 
enhanced when MSCs undergo functional polarization toward the inhibitory phenotype on 
exposure to various pro-inflammatory cytokines such as IFN-γ, TNF-α, IL-1α or IL-1β 
(24,25,34-43). A unique paradox of MSCs is their equal ability to behave as antigen-
presenting and cross-presenting cells under similar conditions. Regardless, IFN-γ remains 
the first key licensing agent for MSC suppressor function. There is strong consensus that 
across species IFN-γ augments MSC suppressor function (through distinct effector 
pathways). In vitro MSC inflammatory “licensing” better recapitulates what likely happens in 
vivo once MSCs are transfused into patients with dysregulated immune responses or with 
systemic inflammation, including sepsis (25-32). In this context, Toll-like receptor (TLR) 
activation could strongly and variably modify MSC immune properties depending on the 
ligand, kinetics and strength of the stimulation (25). In fact, all measurable immunological 
features of MSCs, both at phenotypic and functional levels, depend on their activation status 
at the time of interaction with effector cells, although variability may be observed among 
different donors (36) and between fresh and thawed MSCs (38). Thus, if these functional 
assays aim at assessing the immune regulatory functions of MSCs for clinical purposes, 
comparing the results with both resting and licensed MSCs would be most informative, 
regardless of the species and tissue origin. Different protocols of MSC licensing are available 
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from the literature. IFN-γ is sufficient for licensing and should be used to deploy a functional 
phenotype; however, its effect is amplified by TNF-α. For instance, the addition of 100 IU/mL 
(10 ng/mL) IFN-γ and 15 ng/mL TNF-α for 40 hours of culture is adequate to obtain MSC 
activation before their challenge with immune effector cells (25,44); however, other licensing 
protocols may be suggested to trigger MSCs and make them become efficient 
immunomodulatory cells.   
We suggest that standard immune plasticity assay be based on IFN-γ + TNF-α used as 
a model in vitro priming agent. The issue then arises about how MSCs are investigated 
after licensing.  
1.2. MSC immunophenotyping as part of the immune plasticity response 
Flow cytometry may be used to investigate the expression of cell-surface markers for 
characterizing MSC immunological properties.  A traditional definition of a quiescent MSC is 
that of an MHCI-expressing cell lacking MHCII or co-stimulatory molecule expression 
(45,46). However, IFN-γ–primed MSCs robustly upregulate markers such as MHCI and 
MHCII molecules, immune modulatory molecules (CD200, CD274/PD-L1/B7-H1), 
cytokine/chemokine receptors (CXCR3, CXCR4, CXCR5, CCR7, CD119/IFN-γ receptor), 
adhesion molecules (CD54, CD106), DNAM ligands (CD112, CD155), NKG2D ligands 
(macrophage inflammatory complex [MIC] A/B, UL binding protein 1,2,3), and Notch 
receptors (Jagged-1) (21,22,24). Intriguingly, human MSCs do not upregulate co-stimulatory 
molecules (CD80, CD86) in response to IFN-γ, and immune modulators such as TGF-β can 
markedly blunt MHCII upregulation in response to inflammatory stimuli. MSCs express TLR-3 
and TLR-4 and will respond to their respective agonists, double-stranded RNA (dsRNA) and 
lipopolysaccharide (LPS), which may also help in examining MSC immunomodulatory 
properties (24,47). MSC culture conditions and its impact on immune plasticity could be 
assessed as part of product characterization since the expression of many of these markers 
and implied immune plasticity may change as a result of culture conditions, post-
cryopreservation and inflammatory priming (25,39).   
As an aggregate suggestion, immunophenotypic analysis of an expanded cell product 
immediately before banking (if relevant), as well as at the time of transfusion to human 
subjects, may provide mechanistic insights into intra- and interstudy variation in 
clinical response among patients. 
1.3. Culture modalities and in vitro cell responder assays 
During in vitro MSC expansion, cell culture variables should be documented because of 
possible impact on immune plasticity response.  Variables of interest are cell density at the 
time of passage, number of population doublings (in complementarity to number of 
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“passages”), culture medium (fetal bovine serum, platelet lysates, “defined” medium) and 
growth factors used.  For co-culture experiments, especially with mixed lymphocyte reaction 
(MLR), MSCs can be used as either adherent cell monolayer or in suspension; in both cases 
different MSC/immune effector cell ratios should be tested to assess MSC veto functions on 
MLR. Both unselected peripheral blood mononuclear cells (PBMCs) or purified immune 
effector cells can be used, but the latter usually provide more reproducible results because of 
the lack of confounding third-party cells (monocytes in particular). A high viability of immune-
responding cells is a crucial factor, given the anti-apoptotic activity of MSCs. Monocyte 
content of PBMCs from different normal donors may vary dramatically and this may lead to 
biased results due to different degrees of in vitro licensing process mediated by variable 
monocyte concentrations. Consequently, the use of purified immune cell subsets would 
minimize group variability in assays aimed at studying MSC immune regulation, unless a 
precise quantification of monocyte content, as a fraction of PBMCs, is provided. Concerning 
selection methods, immunomagnetic positive selection may lead to non-specific triggering of 
the target molecules, so indirect negative selection leading to highly purified samples (>95%) 
would be preferable (36). The technique used to activate responder cells may also have an 
impact on the measured potency of MSCs. Different types of stimuli have been used to 
trigger activation of immune effector cells in the presence of MSCs and range from MLR to 
specific antigens (21,41,42). For T cells, common stimuli are phytohaemagglutinin (PHA), a 
polyclonal stimulus leading to robust activation (20), and monoclonal antibodies against CD2, 
CD3 and CD28, which induce a more “physiologic” responder cell activation (43). This 
complexity, coupled with the use of unfractionated PBMCs versus purified T-cell responders, 
may add to the challenge in meta-analyzing intergroup results. In the human setting, a large 
number of MSC:immune effector cell ratios has been tested to assess the best coculture 
conditions to unravel immune regulatory effects, thus showing that the modulation of immune 
functions in vitro requires the presence of adequate numbers of MSCs. A ratio of MSCs to T 
cells of 1:5-10 is generally suitable to obtain a measurable effect (36,44), but a ratio of 1:1 or 
1:5 would be preferable when MSCs are co-cultured with B cells (6,36,40,44) or natural killer 
cells (25,36,44,48,49).  
For NK cells, allogeneic stimulation with irradiated target cell lines (i.e. K562) is 
commonly used, but is not always reproducible. Alternatively, IL-2 priming leads to strong NK 
cell activation and seems to give more reproducible results, although fresh or activated NK 
cells may have different efficiency in recognizing and lysing allogeneic MSCs (48,49). 
MSCs can suppress immunoglobulin production by B cells (6,40,50). Cytofluorimetric 
evaluation of CD38/CD138 upregulation and parallel downregulation of CD20 seems to be a 
good approach to study the differentiation of memory B cells to plasma cells. ELISA or 
ELISpot can be used to monitor whole or specific immunoglobulin secretion by MSCs (51).  
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Different groups have studied a possible role of regulatory T cells (Tregs) in 
immunomodulation, with contrasting results (36,41,52). However, suitable assays to 
demonstrate the ability of MSCs to maintain or induce Treg expansion seem to be 
cytofluorimetric quantification of the proportion of CD4+/CD25+/FoxP3+/CD127- cells after 
co-culture with MSCs, and western blot and real-time PCR assay of FoxP3 expression, with 
functional evaluation of the regulatory potential of resulting T cells to fully confirm the results 
(52). 
MSCs can also affect differentiation of monocytes to macrophages and dendritic cells, 
as well as their maturation, migration and functions. Monocyte differentiation can be studied 
by showing CD80, CD86 and HLA-DR upregulation and CD14 downregulation with activation 
(53). Maturation of monocyte-derived dendritic cells can be shown by studying the 
upregulation of MHCI and MHCII, CD11c and CD83 (53). Similarly, MSC effects on 
macrophages should be carefully characterized, as macrophages play a major role in many 
diseases, i.e. myocardial infarction, stroke and sepsis, for which MSCs have been suggested 
as possible therapeutic strategy. Assay of cytokine production (IL-10, TNF-α) and expression 
of macrophage 1 and 2 (M1/M2) surface markers, such as CD14, HLA-DR and CD206 may 
be used to evaluate the influence of MSCs on monocyte polarization towards macrophages 
(21,24,25,53-55). The activation protocol that seems to be more useful to discriminate 
between TLR-4-dependent MSC1 phenotype (MSC releasing mostly pro-inflammatory 
cytokines, such as IL-6, IL-8, or TGF-β) and TLR-3-dependent MSC2 phenotype (MSC 
producing immunosuppressive molecules, such as IL-4, IL-1RA, IDO and PGE2) is based on 
the short incubation (1 hour) with LPS (10 ng/mL) or poly(I:C) (1 µg/mL), respectively, 
followed by further 24–48 hour incubation in growth medium (24).  
Only a few studies have investigated MSCs and neutrophil interactions (56,57). 
Human neutrophils, usually obtained from peripheral blood of normal volunteers, can be 
isolated with standard density-gradient separation methods (56) or high-purification 
procedures by positively removing all contaminating cells expressing CD3, CD56, CD19, 
CD36, CD49d, and Gly-A (57). The potential advantage of the latter method is that cell 
preparation is devoid of cells that might release factors influencing MSC and neutrophil 
functions regardless of their reciprocal interaction (57); consequently, high-purification 
procedure would be preferable to obtain more reproducible results. In any case, neutrophils 
should be manipulated under endotoxin-free conditions to avoid activation before co-culture 
with MSCs (56,57). Different stimuli (e.g., lipopolysaccharide, poly(I:C), phorbol esters), 
ratios of neutrophils to MSCs (from 1,000:1 to 10:1, in direct contact or in Transwell® 
conditions) and functional assays (e.g., CD16 and CD11b expression as surrogate markers 
of neutrophil viability and activation, respectively; ELISA for cytokine detection; superoxide 
anion release for respiratory burst quantification) may be used to assess the effects of MSC–
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neutrophil interactions (56,57). The choice of one kind of stimulus rather than others would 
depend on which cell type needs to be activated to assess a specific effect. Poly(I:C) addition 
leads only to MSC activation via TLR3, as this receptor is not expressed by PMN (57), and 
consequently the observed phenomena do not depend on the simultaneous PMN activation. 
By contrast, LPS and phorbol esters activate both PMN and MSCs and the subsequent 
observed phenomena depend on the effects induced on both cell types. 100:1 and 10:1 
PMN:MSC ratios and direct contact determine to the most evident effects on PMN survival, 
CD16 and CD11b expression, cytokine production and respiratory burst; all these 
phenomena may be assessed for a complete characterization of MSC effects on PMN; 
however, CD16 and CD11b expression could be used as surrogate markers of neutrophil 
viability and activation, respectively (56,57). 
In summary, the use of purified responders (as opposed to unfractionated PBMCs) 
coupled with a more “physiologic” activation stimulus may be widely practicable and 
provide more generalizable guidance in examining the relative functional potency of 
MSCs and as a companion to clinical trials. 
1.4. MSC cellular biochemistry 
Activation of IDO and iNOS is a pivotal mechanism in lymphocyte inhibition with MSCs, but 
species-specific differences exist. For example, after inflammatory priming, human MSCs 
express extremely high levels of IDO and low levels of iNOS (23,58), which is opposite to 
that seen with mouse MSCs (59). The in vitro functional relevance of IDO bioactivity can be 
readily shown by use of the specific inhibitor L-1 methyltryptophan (L-1MT), which completely 
abolishes the inhibition of T-cell proliferation mediated by human MSCs (23,58). An array of 
potential complimentary suppressor pathways driven by MSCs includes heme oxygenase-1, 
soluble HLA-G5 and other secreted factors such as TGF-β, PGE2, galectin and tumor 
suppressor gene 6 (TSG-6) (21,25,53). Importantly, the MSC response to IFN-γ leads to 
increased expression of pro-inflammatory cytokines/chemokines such as IL-6, CCL2, CCL7 
and CCL8. It is generally accepted that IDO bioactivity is central to the suppressor function of 
human MSCs and that IFN-γregulation leads to massive transcriptional IDO induction.  
Therefore, investigating the IDO response should be central to an in vitro regulation 
assay. Analyzing the transcriptional modulation of immune effector genes as part of 
the IFN-γ response could be further considered. 
1.5. Animal models for in vivo assays assessing human MSC regulatory properties 
Most in vivo experimental models assessing MSC immunomodulation are based on rodent 
species, with some exceptions involving non-human primates (60). Mouse models have been 
used to test the efficacy of MSC transplantation for the treatment of acute GvHD 
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(21,26,27,61-63), neurological (30,31) and systemic (32) autoimmune diseases, sepsis 
(28,55) and acute renal (29) and lung injury (64), as well as other pathological conditions 
(21). Two main issues should be considered when investigating the activity of MSCs in pre-
clinical models: whether to measure their immunosuppressive potency or elucidate the 
mechanisms underlying the therapeutic activities.  
Regardless of the general concerns about validity of mouse models, murine MSCs 
may have a significant number of differences as compared with human MSCs. Some 
differences involve culture conditions and modalities of their expansion, as mouse MSCs 
require a much longer time to expand under standard culture conditions than human MSCs. 
In terms of the molecular pathways of immunosuppression, human and mouse MSCs are 
relatively similar in the predominant use of the mammalian target of rapamycin pathway. 
However, human MSCs preferentially use IDO and murine MSCs selectively use iNOS in 
immunosuppression (23). IDO and iNOS are modulated by different inflammatory molecules; 
therefore, the murine microenvironment does not necessarily provide conclusive information 
about MSC regulation in patients.  As well, caution should be used in interpreting data 
obtained from animal models related to the administration route. Intravenous injection of 
MSCs in mice is notoriously difficult because of the extremely high incidence of lethal 
pulmonary embolism, even with subtherapeutic doses. Some groups have used the 
intraperitoneal route, with variable outcome, because the trafficking of MSCs from this site 
has yet to be defined. The alternative approach has been to inject human MSCs into mice. 
Although human MSCs can improve a number of mouse models, most murine cytokines with 
MSC “licensing” activity do not cross-react with the corresponding human receptors, which 
may confuse the information able to be obtained.   
The models may have fundamental biases, but the reproducibility of an animal model 
could be a great advantage in comparing different MSC preparations. In several conditions, 
including experimental arthritis and GvHD, the precise time for MSC administration for 
effective therapeutic activity has been defined. Therefore, an animal model would eliminate 
patient variability and facilitate an informative comparison of MSC lots and their potential 
manipulation. Although not applicable to a routine cell therapy laboratory, an initial in vivo 
characterization would set the stage to identify the main criteria for the selection of highly 
effective MSC preparations. Nevertheless, data obtained from in vivo studies in rodents 
should be critically evaluated. 
Considering the substantial difficulties in obtaining clear and informative mechanistic 
and potency data from delivery of human MSCs to xenorecipient animal models, 
conclusions on how to conduct clinical trials should be drawn with caution. 
10 
 
 
Conclusions 
Besides having regenerative properties for some tissues, cultured MSCs are mostly used in 
the clinical setting for regulating the immune response. The functional potency of MSCs 
should be quantified by standardized immune assays with purified responders as a scientific 
component of clinical trials. In the same way, immune cell populations could be prospectively 
analyzed in patients receiving MSC therapy. The final aim of methodological standardization 
is to obtain shared, reproducible and consistent data that may validate MSC-based clinical 
approaches as a potentially useful treatment for immunological diseases. The sincere hope 
of this working proposal paper is to contribute to the general discussion in the MSC scientific 
world, thus leading soon to shared guidelines and common protocols for the immunological 
characterization of MSCs for clinical use, in order to achieve comparable and unambiguous 
results on MSC efficacy in human diseases (65). 
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Box 1 
Suggestions for the assessment of regulatory properties of human MSCs 
1. A standard immune plasticity assay should be implemented by using IFN-γ + TNF-α as model in vitro priming 
agent. 
2. Functional analysis of an expanded cell product may provide mechanistic insights on intra- and inter- study 
variance in clinical response amongst patients. 
3. The use of purified responders would be widely practicable and should provide more generalizable guidance 
on relative functional potency of MSCs and as a companion to clinical trials. 
4. Interrogating the IDO response as part of an in vitro licensing assay should be considered central. 
5. Conclusions based on xenorecipient animal models on how to conduct clinical trials should be drawn with 
caution. 
6. The prospective hypothesis-driven analysis of lymphocyte populations in patients groups treated with MSC 
should be encouraged. 
7. Clinical analysis should also include the monitoring of whether injected MSCs are the target of an immune 
response. 
 
 
